Breast Cancer Lung Late Effects (BELLE)
This study will use CT imaging, pulmonary function tests, and blood samples to examine the differences in pulmonary vessel radiation damage between patients treated with standard X-ray therapy and those treated with proton therapy.
This project involves repeat chest computed tomography (CT) imaging and blood draws in subjects with breast cancer with radiation treatment to the affected breast and chest wall. The investigators are studying women receiving one of 2 types of radiation, either conventional X-rays (IMRT) or protons at the University of Florida Health Proton Therapy Institute (UFHPTI).
These subjects typically would not receive follow-up chest CTs as per standard of care. All subjects will have received a pre-treatment chest CT scan as part of the treatment planning process. The investigators will enroll 30 subjects in the X-ray treatment group and 25 subjects in the proton group.
The investigative team has recently solved the technical challenges of extracting and characterizing lung vascular anatomy from clinical CT images of the chest and used these tools to characterize acute and chronic changes to pulmonary vascular structure in breast cancer patients receiving radiation to the chest wall for treatment of their cancer.
- Ages 18 years old and older.
- Breast cancer patients who have Stage II or higher disease and who are scheduled to receive conventional X-ray RT (n=30) or proton therapy (n=25) to the breast and chest wall for the treatment of breast cancer will be enrolled in this study.
- Patients must sign informed consent meeting all federal and institutional guidelines prior to any radiation treatment and/or research interventions.
- Patients not willing or able to submit to repeat chest CT scans with injected vascular contrast and blood draws at the Department of Radiology at UF Shands in Gainesville, or Shands Jacksonville Hospitals.
- Pregnant women are excluded because of possible radiation risk to the fetus.
- Patients who have previously had radiation treatment where any portion of the lung received greater than 5 Gy of radiation exposure.
- Women with bilateral breast cancer or metastatic disease to sites near the chest where additional radiation exposure to any portion of the lung of greater than 5 Gy is anticipated.
- Because breast cancer is rare in men, males are excluded.
- Women with adverse reaction to all common CT contrast agents.
For additional study information, please contact John Lybarger:
- 352-265-0680 ext. 87829
KeywordsBreast Cancer, Radiation Toxicity, CT chest scans, clinical pulmonary toxicity, Breast diseases; Neoplasms; Skin Diseases
Principal InvestigatorWalter O'Dell
Sponsoring GroupDepartment of Radiation Oncology
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.